Generate your proprietary antibodies by de novo protein design in 6 weeks.
Including developability anticipation.
We offer AI-designed developable antibodies and nanobodies, wet-lab validated, from your antigen sequence.
No immunisation, no phage display, no animal.
Some of our clients, wet-lab, R&D and computing partners
Are you struggling to generate reliable and precise antibodies?
Are you frustrated by the complexity and difficulty of generating precise antibodies against your targets?
Are you tired of time-consuming mAbs generation campaigns and betting on uncertain results?
Are you part of the 86% of labs suffering from the lack of reproducibility?
If you answered yes to at least one of those questions, take a moment to read on to discover how EVOBodies™ can bring you more confidence.
Developability issues are the leading cause of failure in early antibody development. (Raybould et al., PNAS 2019)
And when developability issues show up, you have two choices.
First is to push forward anyway with impurities, low productivity, difficulties.
Second is go back to a new cycle with associated costs and time lost.
EVOBodies™ precisely designs your mAbs under developability constraints, to give you the highest chances of success in the subsequent stages.
Three opportunities to start generating or improving your mAbs with EVOBodies™
You want to start a brand new project and you don't have candidates yet
Let's design you mAbs by de novo protein design, from your antigen sequence, and screen them for developability from the start.
Get sequences in 6 weeks, wet-lab validated in 12.
You have a reference sequence of your mAb
Let's design your mAb around an existing sequence, yours or from the literature, for better developability, or for design freedom informed by prior art.
You have candidates
Under NDA, share the sequences you’ve selected after immunisation or phage display. We check developability and specificity before you commit to scale-up.
Your EVOBodies™ pipeline for antibody generation or optimisation
What's even better? EVOBodies™ works for any antigen, including:
little or non-immunogenic
toxic to the host
highly conserved
targeting vital functions
Meet Philippe Herman, CEO of Immunochem and passionate innovator in Life Sciences
Hello, I’m Philippe Herman ! I have been evolving for +12 years on the intersection of biophysics and computational biology.
I authored 20 papers, a PNAS and was invited to write a Science perspective around the hospital-acquired infections.
I am passionate about how technique can help Science. During my research, I needed of precisely designed molecules against my antigens of interests.
This inspired me to develop IMMUNOCHEM’s EVOBodies™ platform, making it accessible to our clients and partners.
How to start your journey with IMMUNOCHEM and generate your antibodies?
Engagement is progressive. You never commit to the next step before the previous one has been a success either for the generation, redesign or developability check.
Step | What you get | Time |
|---|---|---|
Feasibility assessment | A custom score that shows you how much confidence we can have in generating antibodies against your target. It measures design compatibility (not a guarantee of success in the lab). | Days (Free) |
Prototyping study | A scaled-down run that proves the pipeline works end to end on your target. | 2 weeks |
Antibody generation | 100K+ antibody sequences are generated under developability constraints, informed by molecular dynamics. Expression and wet-lab validation are performed on the best candidates. | From 6 weeks |
Bioconjugation | Your antibodies turned into a targeted delivery vector. | Scope dependent |
Frequently asked questions
After our first discussion, we'll produce your free feasibility study in days, showing the confidence score for the next phases. Once you decide to move forward, you'll receive your designed antibody sequences after 6 weeks, wet-lab validated molecules from 12 weeks.
Antigen sequence is enough.
Every project starts with a free feasibility study, run before any commitment. We score your target from its 3D structure and tell you how much confidence we can have in generating antibodies against it. If that confidence is low, we say so plainly and we don't move forward, at no cost to you.
Immunochem was founded in 1998 and spent its first two decades supplying high-quality research antibodies, with a speciality on small molecules. Since 2023, the company focuses on the discovery and generation of antibodies by computational design, backed by wet-lab validation.
Whatever the format (mAb, nanobody), Immunochem delivers research-grade material and transfers the validated sequence and expression construct if appropriate. Gram-scale production runs with contract manufacturers.
The design work is computational and delivered digitally, so we serve customers worldwide from Belgium. Shipment of synthesised molecules follows standard research-reagent export rules, and no restriction applies in the European Union, the United Kingdom, Switzerland, the United States, India or China.
If you want to achieve your scientific goals, you know there are only two possible choices.
The first choice is to continue as you always have: trying to generate antibodies through traditional methods, without certainty about the molecules obtained or their developability.
Or you have this second choice: To invest in confidence and rational antibody design through our EVOBodies™ platform, to receive your designed antibody sequences in 6 weeks only.
Even against the most complex targets.
Without randomness.
We know you can succeed by following a controlled process, like our other clients who trust us.
